# Staccato Apomorphine Single and Multi Dose PK

> **NCT03822364** · PHASE1 · COMPLETED · sponsor: **Alexza Pharmaceuticals, Inc.** · enrollment: 56 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** 009-1
- **DRUG:** active comparator
- **DRUG:** 009-0
- **DRUG:** 009-2
- **DRUG:** 009-3
- **DRUG:** 009-4
- **DRUG:** 009-5

## Key facts

- **NCT ID:** NCT03822364
- **Lead sponsor:** Alexza Pharmaceuticals, Inc.
- **Sponsor class:** UNKNOWN
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-26
- **Primary completion:** 2019-03-26
- **Final completion:** 2019-03-26
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2019-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03822364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03822364, "Staccato Apomorphine Single and Multi Dose PK". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT03822364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*